Relaxant effect of U0126 in hemolysate-, oxyhemoglobin-, and bloody cerebrospinal fluid-induced contraction in rabbit basilar artery.
OBJECTIVE
It has been suggested that mitogen-activated protein kinase (MAPK) is involved in cerebral vasospasm after subarachnoid hemorrhage. The present study was undertaken to explore the inhibitory effect of U0126, a novel MAPK inhibitor, in the contraction of the rabbit basilar artery by 3 spasmogens: hemolysate, oxyhemoglobin, and bloody cerebrospinal fluid (CSF) from patients with vasospasm.


METHODS
The contraction and relaxation of rabbit basilar arteries were measured by isometric tension. MAPK immunoprecipitation was assessed by Western blot analysis.


RESULTS
(1) Pretreatment of the rabbit basilar arteries with U0126 reduced contractions to hemolysate, oxyhemoglobin, or bloody CSF applied subsequently. (2) In the absence of endothelial cells, U0126 produced an inhibitory effect similar to the contractions induced by hemolysate, oxyhemoglobin, or bloody CSF. (3) U0126 relaxed the sustained contraction induced by hemolysate, oxyhemoglobin, or bloody CSF. (4) Hemolysate, oxyhemoglobin, and bloody CSF enhanced MAPK immunoprecipitation. (5) U0126 reduced MAPK immunoprecipitation induced by hemolysate, oxyhemoglobin, and bloody CSF. (6) Hemolysate, oxyhemoglobin, and bloody CSF significantly increased MAPK activity in the rabbit basilar artery. (7) U0126 abolished the effect of hemolysate, oxyhemoglobin, or bloody CSF on MAPK activation.


CONCLUSIONS
This study demonstrated a role of MAPK in the contraction of rabbit basilar arteries by hemolysate, oxyhemoglobin, and bloody CSF. MAPK inhibitor U0126 may be useful in the treatment of cerebral vasospasm.
Zubkov
A Y
AY
Department of Neurosurgery, University of Mississippi Medical Center, Jackson, MS 39216-4505, USA.
Rollins
K S
KS
McGehee
B
B
Parent
A D
AD
Zhang
J H
JH
D000818:Animals; D001488:Basilar Artery / Q000187:drug effects* / Q000201:enzymology / Q000502:physiology; D015153:Blotting, Western; D002070:Butadienes / Q000008:administration & dosage*; D002555:Cerebrospinal Fluid / Q000502:physiology; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004789:Enzyme Activation / Q000187:drug effects; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005260:Female; D006454:Hemoglobins / Q000494:pharmacology*; D006461:Hemolysis / Q000502:physiology; D066298:In Vitro Techniques; D007537:Isometric Contraction / Q000187:drug effects; D008297:Male; D020928:Mitogen-Activated Protein Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism; D009570:Nitriles / Q000008:administration & dosage*; D010108:Oxyhemoglobins / Q000494:pharmacology*; D011233:Precipitin Tests; D011817:Rabbits; D014665:Vasodilator Agents / Q000494:pharmacology; D020301:Vasospasm, Intracranial / Q000139:chemically induced / Q000188:drug therapy*
D002070:Butadienes; D004791:Enzyme Inhibitors; D006454:Hemoglobins; D009570:Nitriles; D010108:Oxyhemoglobins; C113580:U 0126; D014665:Vasodilator Agents; D020928:Mitogen-Activated Protein Kinases